CINGW Company Profile and Key Details

Average 10-day trading volume of 25.70 thousand shares is below the 3-month average of 48.77 thousand, indicating normal recent market interest.

Cingulate Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 153496.01%. The prior quarter beat by 19.23%. Over the last six quarters, Apple has recorded several small beats. These include 3.5% in May 08, 2025.

Cingulate Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.87. This means the shares are trading below this model’s fair value.

Cingulate Inc. (NASDAQ:CINGW) shares are down -79.45% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cingulate Inc. trading at a premium to the broader market with a P/E of -1.61.

Our AI price prediction model suggests that Cingulate Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 159.37%, with price expected at $0.09 by November 24, 2023, within a range of $0.04 to $0.13

Cingulate Inc. (NASDAQ:CINGW) closed at $0.03 USD, losing -$0.01 (-13.47%) from the previous close of $0.04. The stock is currently mid-range between its 52-week high and low $0.03 and $0.04. With a market capitalization of about $234.35 thousand, Cingulate Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.77). Key stats such as the average daily volume over the past year has been around 35.46 thousand shares, in line with its 52-week average. Headquartered in Kansas City, KS, Cingulate Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raul R. Silva, the company employs approximately 13 people and listed since December 08, 2021. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders.

Cingulate Inc. trades at a P/E ratio of -1.61, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.21 reflecting a rich premium to book value. The P/FCF stands at -2.04, also below market averages. Compared to sector medians, Cingulate Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.